j9

J9 is an inhibitor of Glucocorticoid resistance. J9 reverses Dexamethasone Resistance in T-cell Acute Lymphoblastic Leukemia.

Dimethylcurcumin (ASC-J9) 是雄激素受体降解增强剂，能够有效抑制耐药性前列腺癌细胞增殖和侵袭。

YJ9069是一种针对CDK12 CDK13P的选择性ROTAC降解剂，其在VCaP细胞中的IC50达到22.22 nM。该化合物能迅速引起CDK12 13的降解，进而导致基因长度依赖性的转录延长缺陷，从而引发DNA损伤和细胞周期的停滞。在实验中，YJ9069能有效地抑制特定前列腺癌细胞亚群的增殖，并在动物模型中显著地抑制前列腺肿瘤的生长。

FJ9 is a FZD7 inhibitor which disrupts protein-protein interaction between Frz7 and the PDZ domain of DVL, and induces apoptosis in melanoma cell line and non-small cell lung cancer cell line.

UAWJ9-36-3 is a SARS-CoV-2 Protease inhibitor (IC50 = 54 nM). UAWJ9-36-3 showed potent binding and enzymatic inhibition against the Mpro's from SARS-CoV-2, SARS-CoV, MERS-CoV, HCoV-OC43, HCoV-NL63, HCoV-229E, and HCoV-HKU1. UAWJ9-36-3 is a promising candidate to be further developed as a broad-spectrum coronavirus antiviral.

UAWJ9-36-1 is a SARS-CoV-2 Protease inhibitor (IC50 = 51 nM). UAWJ9-36-1 showed potent binding and enzymatic inhibition against the Mpro's from SARS-CoV-2, SARS-CoV, MERS-CoV, HCoV-OC43, HCoV-NL63, HCoV-229E, and HCoV-HKU1. UAWJ9-36-1 is a promising candidate to be further developed as a broad-spectrum coronavirus antiviral.

SJ988497是一种PROTACJAK2降解剂，有效地抑制CRLF2重排(CRLF2r)细胞增殖并降解CRBN新底物GSPT1。该化合物由Ruxolitinib衍生物、连接子以及CRBN配体Pomalidomide构成，可作为急性淋巴细胞白血病(ALL)研究用途。

SJ995973是一种高效的溴结构域和外末端 （BET）蛋白质降解剂，是一种具有潜在抗癌活性的 BET PROTAC。

Estradiol 3-sulfamate (BLE 00084) 是一种具有口服活性和高效性的甾体雌酮硫酸酯酶（ES）抑制剂。Estradiol 3-sulfamate 对人胎盘微粒体中ES的 K（i）值为73 nM，可用于研究乳腺癌。

JNJ-9676是一种具有口服活性的冠状病毒膜蛋白抑制剂，通过膜蛋白二聚体跨膜结构域形成的结合口袋，从而阻断病毒组装与释放，对新冠病毒和SARS-CoV具有纳米摩尔水平的抗病毒活性。

Cephradine dihydrate is the hydrate form of Cephradine (free base), a semi-synthetic cephalosporin antibiotic. Cefradin inhibits the last stage of bacterial cell wall synthesis by binding to certain penicillin-binding proteins which results in cell lysis. Cell lysis is mediated by bacterial cell wall autolytic enzymes. Cefradin may interfere with autolysin inhibitors.

JNJ-9350为spermine oxidase (SMOX)和polyamine oxidase (PAO)的抑制剂，其对SMOX的IC50值为0.01 μM，对PAO的IC50值为0.79 μM。该化合物主要用于癌症研究领域。

Ichorcumab (JNJ-375) 是一款全人源IgG4抗体，专门与凝血酶 (Thrombin) 相结合。Ichorcumab 通过结合凝血酶外位点 1 来阻止底物的结合，但它不影响凝血酶的催化活性。Ichorcumab 的等型对照为 HumanIgG1kappa, Isotype Control。